Start exploring your own markets for free

🚀 Try for Free

/AI Therapeutics
Invite

Pending to review

Not sure yet

Interested

Not interested

Showing 104 companies

Download list

Company
Fit assessment
Description
Subspaces
Tags
HQ Location
Founding Date
Employees
Total Funding Raised
Last Funding Event
Received on

Metanovas effectively leverages machine learning for drug discovery and repurposing, demonstrating a strong commitment to expanding therapeutic options.

Metanovas develops nutraceutical and cosmeceutical products with revolutionary AI technology. The company's product pipeline includes pharmaceuticals, nutritional supplements, functional foods, and cosmetics, providing patients and consumers with better goods. Metanovas alters how science and AI are used to generate health products.
  • Drug Repurposing
Light Search
Mountain View (United States)202111 - 50$10.00MSeries A, December 3, 2024
Oct 14, 2024

VeriSIM Life effectively leverages machine learning to enhance drug development, discover patterns in drug interactions, and expand therapeutic options, including drug repurposing.

VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. VeriSIM offers a range of translational-based solutions, customized for the pre-clinical and clinical programs. These offerings are all centered around their proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses.
  • Drug Repurposing
Light Search
San Francisco (United States)201711 - 50$21.66MSeries A, $15.00M, January 13, 2022
Oct 14, 2024

Pending.AI effectively utilizes machine learning to enhance drug discovery, pattern discovery, and the development of new therapeutics.

Founded by Professor Mark Waller, Pending AI has developed a comprehensive discovery platform enabled by artificial intelligence and quantum mechanics, ushering in a new paradigm of medicinal innovation where higher-quality small molecule drugs can be developed in a fraction of the time and cost. With operational presences across both Cambridge, Massachusetts, United States and Eveleigh, New South Wales, Australia, Pending AI is actively seeking research-and-development partnerships with pharmaceutical companies, as well as to ascertain interest from investors in the company's upcoming investment round.
  • Drug Discovery Optimization
Light Search
Cambridge (United States)20181 - 10Venture - Series Unknown, January 1, 2021
Oct 14, 2024

REPO4EU effectively leverages machine learning for drug repurposing, discovering new patterns in disease mechanisms, and expanding therapeutic options.

This platform will operate as a data hub for key information, training resources, matchmaking and collaboration in drug repurposing. We offer a world-class mix of applied bioinformatics, innovative diagnostics, curative drug therapies, expertise in repurposed drug patenting, freedom to operate, business development, health technology assessment and multiple options for value creation through licensing and spin-offs.
  • Drug Repurposing
Light Search
Maastricht (Netherlands)202211 - 50NA
Oct 14, 2024

Cancerappy effectively utilizes machine learning and AI to enhance cancer research, discover new therapeutic targets, and optimize drug discovery processes.

Cancerappy designs and develops a platform that uses big data and artificial intelligence to help research against cancer. Luis MartĂ­n Ezama founded it in 2019, with its headquarters in Bilbao in Spain.
  • Drug Discovery Optimization
Light Search
Bilbao (Spain)20191 - 10NA
Oct 14, 2024

Fasttrac leverages machine learning and advanced computational methods to discover novel molecules, optimizing the drug discovery process and expanding therapeutic options.

Fasttrac Enables the discovery of novel molecules for drug development and materials applications, fasttrac repository - contributing services, physics, chemistry, biology, and mathematics-based software services.
  • Drug Discovery Optimization
Light Search
Irvine (United States)201911 - 50NA
Oct 14, 2024

Insitro effectively utilizes machine learning to discover patterns and expand therapeutics, optimizing the drug discovery process.

Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics. In 2018, Daphne Koller established Insitro in South San Francisco, California..
  • Drug Repurposing
  • Drug Discovery Optimization
Light Search
South San Francisco (United States)2018201 - 500$643.00MSeries C, $400.00M, March 15, 2021
Oct 14, 2024

Medvolt effectively leverages machine learning to discover patterns and expand therapeutics, including drug repurposing capabilities.

Developer of biomedical research platform designed to accelerate life sciences research. The company focuses on accelerating drug discovery and development by democratizing access to AI-powered technology and clean data by leveraging a highly modular and data-driven, thereby reducing costs and increasing the probability of success.
  • Drug Repurposing
Light Search
Pune (India)20211 - 10NA
Oct 14, 2024

Illumina specializes in advanced technologies for analyzing genetic material, focusing on DNA, RNA, and protein analysis to support disease research and drug development. Their solutions aim to facilitate personalized medicine through innovative and scalable approaches.

Illumina is an innovative technology and revolutionary assay aiming to analyze genetic variation and function. These studies help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, it strives to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
  • Biomarker Identification
  • Genomic Data Analysis
Light Search
San Diego (United States)19985001 - 10000$1.28BPost-IPO Debt, $500.00M, September 6, 2024
Oct 14, 2024

Quanterix Corporation develops a highly sensitive platform for analyzing individual proteins and small molecules, enhancing clinical diagnostics and drug development. Their technology enables early disease detection and precise treatment methods across various therapeutic areas.

Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come.
  • Biomarker Identification
Light Search
Billerica (United States)2007201 - 500$850.30MGrant, March 29, 2022
Oct 14, 2024

Use "Get more companies" to continue searching, or run a “Deep Dive” for a comprehensive mapping